000282681 001__ 282681
000282681 005__ 20240229155044.0
000282681 0247_ $$2doi$$a10.1093/ejendo/lvad117
000282681 0247_ $$2pmid$$apmid:37675794
000282681 0247_ $$2ISSN$$a0001-5598
000282681 0247_ $$2ISSN$$a0804-4643
000282681 0247_ $$2ISSN$$a1479-683X
000282681 0247_ $$2altmetric$$aaltmetric:153926335
000282681 037__ $$aDKFZ-2023-01827
000282681 041__ $$aEnglish
000282681 082__ $$a610
000282681 1001_ $$aTichanek, Filip$$b0
000282681 245__ $$aEarly mortality critically impedes improvements in thyroid cancer survival through a half century.
000282681 260__ $$aBristol$$bBioScientifica Ltd.$$c2023
000282681 3367_ $$2DRIVER$$aarticle
000282681 3367_ $$2DataCite$$aOutput Types/Journal article
000282681 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1694173841_27135
000282681 3367_ $$2BibTeX$$aARTICLE
000282681 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282681 3367_ $$00$$2EndNote$$aJournal Article
000282681 500__ $$a#LA:C020#
000282681 520__ $$aWe analyze survival in thyroid cancer from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE) over a 50-year period (1971-2020), and additionally consider concomitant changes in incidence and mortality.Population-based survival study.Relative 1-, 5/1 (conditional)-, and 5-year survival data were obtained from the NORDCAN database for years 1971-2020. Incidence and mortality rates were also assessed.A novel consistent observation was that 1-year survival was worse than 5/1-year survival but the difference between these decreased with time. Relative 1-year survival in thyroid cancer (mean for the 4 countries) reached 92.7% for men and 95.6% for women; 5-year survival reached 88.0% for men and 93.7% for women. Survival increased most for DK which started at a low level and reached the best survival at the end. Male and female incidence rates for thyroid cancer increased 3- and 4-fold, respectively. In the same time, mortality halved for men and for women, it decreased by 2/3.We documented worse relative survival in the first year than in the 4 subsequent years, most likely because of rare anaplastic cancer. Overall survival in thyroid cancer patients increased in the Nordic countries in the course of 50 years; 5-year survival was close to 90% for men and close to 95% for women. Even though overdiagnosis may explain some of 5-year survival increase, it is unlikely to influence the substantial increase in 1-year survival. The unmet need is to increase 1-year survival by diagnosing and treating aggressive tumors before metastatic spread.
000282681 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000282681 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282681 650_7 $$2Other$$aanaplastic cancer
000282681 650_7 $$2Other$$adiagnostics
000282681 650_7 $$2Other$$arelative survival
000282681 650_7 $$2Other$$atreatment
000282681 650_2 $$2MeSH$$aFemale
000282681 650_2 $$2MeSH$$aHumans
000282681 650_2 $$2MeSH$$aMale
000282681 650_2 $$2MeSH$$aThyroid Neoplasms: diagnosis
000282681 650_2 $$2MeSH$$aThyroid Neoplasms: epidemiology
000282681 650_2 $$2MeSH$$aDatabases, Factual
000282681 650_2 $$2MeSH$$aFinland: epidemiology
000282681 650_2 $$2MeSH$$aNorway: epidemiology
000282681 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000282681 7001_ $$aLiska, Vaclv$$b2
000282681 7001_ $$aHemminki, Otto$$b3
000282681 7001_ $$aKoskinen, Anni$$b4
000282681 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b5
000282681 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b6$$eLast author$$udkfz
000282681 773__ $$0PERI:(DE-600)1485160-X$$a10.1093/ejendo/lvad117$$gVol. 189, no. 3, p. 355 - 362$$n3$$p355 - 362$$tEuropean journal of endocrinology$$v189$$x0001-5598$$y2023
000282681 909CO $$ooai:inrepo02.dkfz.de:282681$$pVDB
000282681 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000282681 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000282681 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000282681 9141_ $$y2023
000282681 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-26
000282681 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-26
000282681 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-26
000282681 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J ENDOCRINOL : 2022$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000282681 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J ENDOCRINOL : 2022$$d2023-10-21
000282681 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000282681 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000282681 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000282681 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000282681 980__ $$ajournal
000282681 980__ $$aVDB
000282681 980__ $$aI:(DE-He78)B062-20160331
000282681 980__ $$aI:(DE-He78)HD01-20160331
000282681 980__ $$aI:(DE-He78)C020-20160331
000282681 980__ $$aUNRESTRICTED